A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III

Dan Hu1☯, Zhongyu Zhu2☯, Shun Li3☯, Yongqiang Deng4☯, Yanling Wu1, Nana Zhang4, Vinita Puri2☯, Chuyun Wang1, Peng Zou3, Cheng Lei1, Xiaolong Tian1, Yulu Wang1, Qi Zhao2, Wei Li2☯, Ponraj Prabakaran3*, Yang Feng2, Jane Cardosa5, Chengfeng Qin4, Xiaohui Zhou3*, Dimiter S. Dimitrov2☯, Tianlei Ying1*

1 MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China, 2 National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America, 3 Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Fudan University, Shanghai, China, 4 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China, 5 Institute of Health and Community Medicine, Universiti Malaysia Sarawak, Malaysia

☯ These authors contributed equally to this work.

*zhouxiaohui@shphc.org.cn (XZ); mit666666@pitt.edu (DSD); tlying@fudan.edu.cn (TY)

Abstract

Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Immunogenetic analysis indicated that m366.6 is a germline-like mAb with very few somatic mutations from the closest VH and VL germline genes. Importantly, we demonstrated that it potently neutralized DENV both in vitro and in the mouse models of DENV infection without detectable antibody-dependent enhancement (ADE) effect. The epitope of m366.6 was mapped to the highly conserved regions on DIII, which may guide the design of effective dengue vaccine immunogens. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate.

Author summary

Dengue virus infects 50–100 million people each year. Infection is initiated by entry of the virus into cells mediated by the viral envelope glycoproteins. There are four closely related
DENV serotypes, but they all are antigenically distinct, with each comprising several genotypes that exhibit differences in their infection characteristics in both the mosquito vector and in the human host. One of the confounding problems that has faced vaccine and biological drugs development for decades is the inability of antibodies to one serotype to protect against infection by another one. Instead, the induced humoral immune response to one dengue virus infection can enhance the infection and disease processes brought by a subsequent infection with another dengue serotype. In this study, by using a competitive sorting strategy to interrogate a human naïve antibody library, we identified a cross-reactive mAb, designated as m366.6, against the four DENV serotypes. The mAb m366.6 possesses only few somatic mutations from the closest VH and Vλ germline genes and high affinity to DIII. Most importantly, the germline-like m366.6 demonstrated a broad spectrum of neutralization against the four DENV serotypes. Thus, m366.6 is a promising candidate therapeutics and its epitope may imply on the design of effective vaccine immunogens to elicit m366.6-like antibodies in vivo.

Introduction

Dengue virus (DENV) causes the most prevalent mosquito-borne viral disease. Over 2.5 billion people are at risk for infection in over 100 countries, 50–100 million are infected with symptoms, and up to 50,000 die from dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) each year [1,2]. No specific antiviral drug has been available against DENV infection; the only approved vaccine, Dengvaxia, has caused considerable controversy regarding its safety and potential benefits [3–6]. For decades, anti-DENV vaccine and biological drugs development has been hampered by the high sequence divergence (25–40%) among the four DENV serotypes [7,8]. Such divergence leads to the fact that one antibody may not be sufficient to neutralize all DENV infection. Instead, the induced humoral immune response to one DENV infection can enhance the infection and disease processes brought by a subsequent infection with another DENV serotype [2–4]. These findings suggest that the development of new and broadly neutralization antibodies against all the serotypes of DENV could be promising candidate anti-DENV agents, and may also guide the design of effective and safe vaccine immunogens.

The DENV envelope glycoprotein (E protein), which mediates virus entry into cells, is the major neutralizing target of antibodies [9–13]. E protein is a type II fusion protein and consists of three domains: DI, DII, and DIII of which DIII has been proposed to contain a receptor binding domain [14–17]. Recent studies revealed that cross-reactive conserved epitopes exist on DII as well as DIII of the DENV E protein [14,16–18]. During the naturally-occurring primary DENV infection, a large fraction of the antibody repertoire consists of DII-specific antibodies which are, unfortunately, typically poor in neutralization and may increase the likelihood of severe disease upon subsequent infection through a mechanism known as antibody-dependent enhancement (ADE) [18–20]. In contrast, antibodies targeting DIII have proven to be the most potent neutralizing antibodies, but very few could be elicited in naturally infected individuals [18,19,21–35]. Despite this, previous studies indicated that anti-DENV DIII serotype-specific and cross-reactive antibodies could be elicited using DENV DIII as vaccine immunogen [36–43] and in infected humans [44–47]. It has also been demonstrated that the lysine at position 310 on DIII is the critical residue in the cross-reactive epitope [24]. Therefore, the conserved epitope on DIII represents an attractive target for the development of broadly neutralizing DENV antibodies.
Here, we report the isolation of a potent DENV DIII-specific human monoclonal antibody (mAb), designated as m366.6, from a large naïve antibody library constructed by the blood of healthy adult donors. A competitive sorting strategy using a DIII mutant as competitor was applied to identify antibodies precisely targeting the conserved neutralizing epitope. To our knowledge, m366.6 is the first human mAb isolated from a naïve antibody library which could neutralize all the four serotypes DENV viruses. Importantly, both heavy and light chain genes of m366.6 are very close to their putative germline predecessors. Its fully human origin, the germline-like nature, combined with high-affinity and broad neutralizing activity toward all DENV serotypes, suggest that m366.6 is a promising candidate antiviral agent and may also provide a unique template for designing effective dengue vaccine immunogens.

Results

Isolation and generation of DENV1-4 broadly neutralizing mAbs

We previously prepared some large naïve antibody libraries using peripheral blood B lymphocytes of non-immunized healthy donors and used them for panning/screening against viral and cancer targets [48–55]. In this study, we used a competitive library sorting strategy to isolate broadly neutralizing antibodies against DENV1-4 (Fig 1A and 1B). The yeast-displayed naïve single chain antibody fragment (scFv) library was used to screen against the biotinylated DENV DIII, and, importantly, ten times concentration unbiotinylated DIII K310E mutant was used as the competitor. The yeast cells were selected to present the antibody-expressing cells that could bind well to the wild-type DIII instead of the DIII mutant, resulting in the isolation of antibodies that can target the cross-reactive neutralizing epitopes covering the residue Lysine310 [55]. Potent enrichment was achieved after four rounds of sorting, and a panel of antibodies were identified (Fig 1B). Two antibodies, designated as m360 and m366, bound...
potently to DENV DIIIs. Their scFv gene were fused with human IgG1 Fc for protein expression, and surface plasmon resonance (SPR) experiments were used to evaluate the antigens binding. The equilibrium dissociation constant ($K_d$) of m360 for the DENV1-4 DIIIs were 5.8 nM, 5.1 nM, 0.1 nM and 8.3 nM, respectively. The mAb m366 displayed a broader binding profile compared with that of m360, with the $K_d$ of 3.3 nM, 1.2 nM, 1.1 nM and 12 nM to DENV1-4, respectively (Table 1, S1 and S2 Figs).

To further improve the affinity of m360 and m366 with the four DENV serotypes, we constructed a mutant library using the error-prone PCR technologies. Following three cycles of mutagenesis and selection, two clones were identified from the enriched pool of yeast sorting, designated as m360.6 and m366.6. Biacore analysis showed that the cross-reactive binding activities of m360.6 and m366.6 to all 4 DIIIs were preserved after the affinity maturation process. The $K_d$ of m360.6 for the DENV1-4 DIIIs were 0.8 nM, 0.3 nM, 0.3 nM, and 1.9 nM respectively, which demonstrated that m366.6 could bind to all the four serotype DENV viruses with high avidity (Table 1, Fig 2). We also assessed the binding specificity of m366.6 by ELISA, and the results showed that m366.6 had weak cross-reactivity with Zika virus (ZIKV) DIII and no binding with other irrelevant antigens (S4 Fig).

Neutralization activity in vitro

Next, we assessed the neutralization capacity of m360.6 and m366.6 against the four DENV serotypes using a DENV luciferase reporter viral particle (RVP) neutralization assay. We used DENV RVPs against the four dengue serotypes that are common strains in DENV research: DENV-1 (WestPac 74), DENV-2 (S16803), DENV-3 (CH53489), and DENV-4 (TVP360). The luminescent reporter expression was proportional to the number of RVPs added to BHK DC-SIGN cells, confirming the linear correlation between the extent of RVP infection and reporter gene expression. In consistent with the Biacore binding results, both m360.6 and m366.6 could neutralize all the four serotype DENV, and m366.6 displayed better neutralization than m360.6, with the 50% neutralization titers (IC$_{50}$) of 22, 2.4, 0.85, and 0.36 µg/ml against DENV1-4 respectively (S5 Fig).

Table 1. Binding kinetics of DENV1-4 DIII-specific mAbs measured by Biacore.

| mAb     | DENV-1 DIII | DENV-2 DIII | DENV-3 DIII | DENV-4 DIII |
|---------|-------------|-------------|-------------|-------------|
| m360    | $k_{on}$ (Ms$^{-1}$) | $1.2 \times 10^{6}$ | $1.7 \times 10^{7}$ | $5.9 \times 10^{7}$ | $9.0 \times 10^{4}$ |
|         | $k_{off}$ (s$^{-1}$)  | $7.0 \times 10^{-3}$ | $8.8 \times 10^{-4}$ | $6.9 \times 10^{-7}$ | $7.5 \times 10^{-4}$ |
|         | $K_d$ (M)    | $5.8 \times 10^{-9}$ | $5.1 \times 10^{-9}$ | $1.2 \times 10^{-10}$ | $8.3 \times 10^{-9}$ |
| m366.6  | $k_{on}$ (Ms$^{-1}$) | $7.6 \times 10^{5}$ | $7.7 \times 10^{5}$ | $1.9 \times 10^{5}$ | $2.7 \times 10^{5}$ |
|         | $k_{off}$ (s$^{-1}$)  | $2.5 \times 10^{-3}$ | $9.3 \times 10^{-4}$ | $2.0 \times 10^{-4}$ | $1.0 \times 10^{-2}$ |
|         | $K_d$ (M)    | $3.3 \times 10^{-9}$ | $1.2 \times 10^{-9}$ | $1.1 \times 10^{-9}$ | $1.2 \times 10^{-8}$ |
| m360.6  | $k_{on}$ (Ms$^{-1}$) | $1.1 \times 10^{6}$ | $3.8 \times 10^{5}$ | $4.1 \times 10^{6}$ | $1.5 \times 10^{6}$ |
|         | $k_{off}$ (s$^{-1}$)  | $3.4 \times 10^{-4}$ | $1.6 \times 10^{-5}$ | $9.4 \times 10^{-7}$ | $5.3 \times 10^{-7}$ |
|         | $K_d$ (M)    | $3.1 \times 10^{-10}$ | $4.2 \times 10^{-11}$ | $2.3 \times 10^{-12}$ | $3.3 \times 10^{-8}$ |
| m366.6  | $k_{on}$ (Ms$^{-1}$) | $3.2 \times 10^{5}$ | $9.6 \times 10^{5}$ | $6.6 \times 10^{5}$ | $3.3 \times 10^{5}$ |
|         | $k_{off}$ (s$^{-1}$)  | $2.5 \times 10^{-4}$ | $2.5 \times 10^{-4}$ | $1.8 \times 10^{-4}$ | $6.2 \times 10^{-4}$ |
|         | $K_d$ (M)    | $7.8 \times 10^{-10}$ | $2.9 \times 10^{-10}$ | $2.7 \times 10^{-10}$ | $1.9 \times 10^{-9}$ |

https://doi.org/10.1371/journal.ppat.1007836.t001
To further evaluate the neutralization breadth of m366.6 IgG against the four DENV serotypes, a standard plaque reduction neutralization assay (PRNT) on BHK-21 cells was performed using DENV1-4 live viruses, including DENV-1 128 (GenBank FJ176780), DENV-1 GZ01/2017 (S6 Fig, isolated from a DENV-1 infected patient in Guangzhou, China), DENV-2 43 (GenBank AF204178), DENV-3 80–2 (GenBank AF317645), and DENV-4 B5 (GenBank AF289029). An irrelevant human mAb G12 was used as the negative control [56], and 2A10G6, a broadly neutralizing mAb against all the four DENV serotypes, was used as the positive control [57,58]. As shown in Fig 3, m366.6 IgG could neutralize all the four DENV serotypes. The 50% neutralization titers (IC$_{50}$) of m366.6 against DENV1-4 was 12.7, 4.57, 5.23, and 23.31 μg/ml respectively (Table 2).

**ADE assay in vitro**

We next used a well-established ADE assay to detect the in vitro ADE effect of m366.6 IgG. A mutated form of m366.6 IgG was also generated containing the leucine to alanine substitutions at positions 234 and 235 (m366.6 IgG-LALA), which lacked binding to Fcγ receptors. The ADE effects of DENV-1 or DENV-2 by m366.6 IgG, m366.6 IgG-LALA, as well as 2A10G6 were measured. Interestingly, neither m366.6 IgG nor m366.6 IgG-LALA presented any ADE effect against different serotypes of DENV (Fig 3F, S7 Fig). In contrast, potent ADE effects were observed for the DII-specific mAb 2A10G6. These results showed that m366.6 IgG is a DENV DIII-specific mAb without detectable ADE effect.

**Immunogenetic analysis**

We further analyzed the sequences of mAbs using the IMGT tool to identify their closest VH and Vλ germline genes. The results indicated that m360.6 and m366.6 originated from different B-cell lineages (Table 3). The m360.6 VH gene was derived from the IGHV2-70 and the
V\lambda gene was from IGLV1-51. In contrast, the m366.6 VH gene was derived from IGHV3-21 and the V\lambda gene was from IGLV3-21. Interestingly, we found that the encoding genes of both m360.6 and m366.6 closely resembled their corresponding germline gene segments. Notably, m366.6 VH and V\lambda gene shared 95.8% and 95.2% sequence identities with the IGHV3-21*01 and IGLV3-21*01 germlines respectively (Fig 4A and 4B). These results indicated that the mAb m366.6 is a germline-like antibody, which, in general, could show better drug properties and lower immunogenicity compared to somatically hypermutated antibodies [59].

Table 2. PRNT\textsubscript{50} values of mAbs against DENV 1-4.

| mAb   | DENV-1 (128) | DENV-2 (43) | DENV-3 (80–2) | DENV-4 (B5) | DENV-1 (GZ01/2017) |
|-------|--------------|-------------|---------------|-------------|-------------------|
| m366.6 IgG | 12.74        | 4.57        | 5.23          | 23.31       | 12.56             |
| 2A10G6  | 1.82         | 1.23        | 2.19          | 1.31        | 1.84              |
| G12     | >200         | >200        | >200          | >200        | >200              |

Table 3. Genetic analysis of the heavy and light chain variable regions of DENV DIII-specific antibodies.

| mAb   | Variable region | Variable region identity (%) | D    | J    | CDR3                         |
|-------|-----------------|------------------------------|------|------|------------------------------|
| \(V_H\) | m360.6          | HV2-70’10                    | 96.6%| D1-1’01 | J3’02 VRTPYWNDGPRGALDI |
|        | m366.6          | HV3-21’01                    | 95.8%| D6-19’01 | J3’02 ARYMAGIWTFDI |
| \(V_L\) | m360.6          | LV1-51’01                    | 93.0%| J2’01  | GAWDRSLSAVV                  |
|        | m366.6          | LV3-21’01                    | 95.2%| J3’02  | QVWARSSDLPNWV                |
To further investigate the immunogenetic characteristics of m366.6-like antibodies, we analyzed in detail the IGHV3-21 recombination frequencies with specific IGHD and IGHJ genes families from naïve immunoglobulin M (IgM) repertoires of 33 health adult donors and neonatal IgM repertoires of 10 newborn babies, using next-generation sequencing data previously generated from our antibodyome studies [48]. By querying the m366.6 sequence from the IgM repertoires, 39 sequences were found to display m366.6-like V(D)J recombination from the genes IGHV-3-21, IGHD1, and IGHJ3 out of a total of 10,498,301 sequences from healthy adult IgM repertoires. In IgM repertoires of newborn babies, a similar recombination frequency was also observed, in which 111 sequences with m366.6-like V(D)J recombination were found from 5,617,227 sequences. Our analysis showed that IGHV3-21 is one of the most frequently used IGHV genes, and identified that many of those sequences sharing a significant degree of resemblance to m366.6 (Fig 4C). In brief, analysis of these data showed the potential of eliciting robust immune responses with the m366.6-like germline antibodies by vaccination.

**In vivo protection study in DENV1-4 infected mice**

To determine whether m366.6 can protect DENV infections in vivo, we firstly used a lethal DENV1-4 infection suckling mouse model. The mice were challenged with DENV1-4 at 200 PFU/mouse via intracranial injection. Four hours later, the mice were treated intracranial with a single dose (100 μg) of m366.6 IgG, m366.6 IgG-LALA mutant and G12 (unrelated antibody control). These animals were monitored for morbidity and mortality daily. As shown in Fig 5, all the mice in control groups died from DENV infection, and most of them died within the first two weeks of viral challenge. Interestingly, there was no significant difference in therapeutic efficacy against DENV1-4 infection between m366.6 and the LALA-mutated m366.6. The m366.6 IgG protected 100% DENV-1, DENV-3, DENV-4 and 83% DENV-2 infection whereas
LALA-mutated m366.6 protected 83% DENV-1, DENV-4 and 67% DENV-2, DENV-4 respectively. Therefore, m366.6 has no detectable ADE as confirmed in both \textit{in vitro} and \textit{in vivo} experiments. We also used the AG129 (types-I and -II IFN receptor deficient) mice to test the therapeutic effect of m366.6 against DENV-2 (S8 Fig). The results showed that all the mice in the control antibody treatment group died while the survival rate of mice can reach 67% in m366.6 treatment group, indicating that the antibody can also protect the lethal infection of DENV-2 in AG129 mice. Taken together, these results indicated that m366.6 can protect DENV1-4 infections \textit{in vivo}.

**Epitope mapping of m366.6**

To map the epitope of the germline-like mAb m366.6 and identify in greater detail the structural basis of DENV neutralization, we employed multiple approaches (Fig 6).

Sequence alignment of different DENV genotypes and mapping of the conserved amino acid residues of DENV DIII showed that four serotypes DENV DIIIs amino acid residues were different from one another between amino acids 300–393 (Fig 6A). Subsequently, serotype 2 derived DIII consensus gene was randomly mutated to construct a yeast-displayed mutant library. Two rounds of sorting of those yeast cells showing expression on surface but lacking the binding to m366.6 was performed. A total of 35 binding escape mutants were aligned with the serotype 2 consensus protein sequence. Mutation frequency at each position was plotted against the residue position number. Similarly, 193 unique DIII sequences derived from naturally isolated serotype 2 dengue viruses from GenBank were also aligned with the consensus sequence (Fig 6B and 6C). The superimposed profiles of the two set of sequences showed that many of the escaped mutations located in the well-conserved area, indicating the broad cross-reactivity of m366.6 to naturally isolated dengue viruses. Besides, the epitope mapping shows that the m366.6 epitope is at close to or partially overlaps the dimerization interface between
domains II and III. These results may explain why m366.6 is a potent cross-reactivity antibody to all the four DENV serotypes.

Furthermore, computational docking of DENV DIII-m366.6 antibody complex was performed using ZDOCK method. We selected the three top scored docked complexes that contained the key residues identified from an experimental epitope mapping approach. One of the top scored docked models exhibited minimum clashes with appropriate protein interface parameters and was used to demonstrate the lactation the potential epitopes and their interactions with m366.6 antibody, which might shed light on the molecular mechanisms of broadly cross-reactive neutralization. Fig 6D showed the docking model of the DIII-m366.6 antibody complex in which these epitopes are highlighted in green surfaces. The docking model revealed a different orientation of antibody binding as compared to the DIII complex structure with Fab 1A1D-2 that was previously determined [35]. The epitope comprised of three structurally proximal regions, residues 305–311 in green, 325, 327 and 361 in dark green, and 383–385 at the C-terminal in lime. One of the key residues, K310, contacts the CDR-L1 of m366.6 which has a germline mutation. In Env-DIII-Fab-1A1D-2 complex structure, the residue K310 contacts the CDR-H1. The hydrophobic residues, Ile and Trp, of CDR-H3 contact the center part of the epitope, and other loops H1, H2, L2 and L3 also involve in the binding. The surface area of the interface between DIII and m366.6 antibody in the model complex is 716 Å², a typical of antibody-antigen interactions. There are six hydrogen bonds likely to form and no salt bridges
at the interface. In brief, the binding regions of the m366.6 may be close to or partially overlaps the dimerization interface between domains II and III, which might indicate the broad cross-reactivity of m366.6 to the four serotypes of DENV.

**Discussion**

Dengue is a disease with a complex immune response orchestrated by host cells partially due to the presence of four serotypes of DENV. Importantly, after a primary DENV infection, one can be protected against or aggravate of a secondary infection with a different serotype, which bring many difficulties to develop an effective vaccine. Thus, it is very urgent to develop an effective and cross-reactive antiviral therapy against DENV infection.

Monoclonal antibodies (mAbs) are of growing importance for protective and pathogenic immune responses to viruses. At present, there are many therapeutic antibodies to treat viral infections under development, such as antibodies for HIV-1, SARS-CoV, MERS-CoV, Nipah and Hendra viruses, and H7N9 influenza virus [48,50,60–66]. Fortunately, screening antibodies from the large naïve libraries has enabled the rapid development of high-affinity human mAbs, especially for the rapid response to the outbreak of emerging viruses and diseases. We recently successfully identified two human germline-like mAbs against MERS-CoV and H7N9 influenza virus from the naïve library, named m336 and m826, respectively [48,50]. They both can naturally exist with very low level of somatic hypermutation in the naïve library with which they have potent binding activity against the envelop proteins of MERS-CoV and H7N9 influenza virus. Most importantly, m336 and m826 all showed highly therapeutic effective in the animal models. Therefore, the naïve library screening can be quickly used to isolate germline-like antibodies that effectively bind to complex protein targets like those in DENV viruses.

How to increase the neutralization breadth is a key issue in developing anti-DENV antibodies. Previous studies revealed two classes of broadly neutralizing antibodies to flaviviruses, including antibodies targeting the conserved epitopes in DII or DIII [16–18,20]. While the conserved fusion loop epitope (FLE) in DII is the immunodominant epitope in E protein, unfortunately, this epitope frequently induced poorly neutralizing and strongly infection-enhancing antibodies via ADE [18–20]. Therefore, DIII represents the ideal target for neutralizing antibodies. In this study, we applied a highly efficient yeast-display-based sorting strategy by using the highly diverse DENV DIIIs as antigen and the competitive sorting technique. By applying this method, we quickly and efficiently identified two human germline-like broad-spectrum anti-DENV mAbs (m360 and m366) from the naïve scFv yeast library using the DIII antigen that make them as promising candidate therapeutics as well as the template for vaccine development. Another class of highly efficient broadly neutralizing antibodies that target the envelope dimer epitopes (EDE) from the secondary acute DENV infection plasmablasts has been identified by Dejnirattisai et al. [67]. These antibodies may especially get through with high somatic mutations from the secondary virus infection. Compared with the highly somatically mutated antibodies, germline-like antibodies typically have better safety and drug-related property [59]. Importantly, the Hendra and Nipah antibody m102.4 is a near germline antibody and exhibited a very good drugability, which was from a similar library that was also used to isolate our m366 and m366-like antibodies. m102.4 was successful as a candidate therapeutic mAb in animal models and was also completed the phase I clinical trial (ACTRN12615003955338) without side effects [64]. To further improve the affinity of m366 with the four serotypes DENV DIIs, we subjected m366 to affinity maturation process, and named it as m366.6. Subsequently, we analyzed m366.6 sequence using the IMGT tool to identify its closest VH and Vλ germline genes. Interestingly, we found that m366.6 is still a germline-like antibody although it went through the mutation process in vitro, with over
95% identities of its VH and V\(\lambda\) genes to the IGHV3-21*01 and IGLV3-21*01 germline respectively.

In order to evaluate the neutralization effect of the m366.6 IgG, we used a standard plaque reduction neutralization with BHK21 cells to measure DENV infection and neutralization. The m366.6 IgG showed broadly neutralization towards the four serotypes DENV as well as a recent DENV isolate from clinical samples. More importantly, m366.6 did not present any ADE effects in different serotypes of DENV. The in vivo study results demonstrated the therapeutic potential of m366.6 against severe DENV1-4 infections. In brief, the m366.6 could neutralize the four serotypes DENV in vitro and protect the DENV infection mouse model in vivo without detectable ADE effects. We therefore expect that m366.6 has a likeness drugability of m102.4 and could be developed as a candidate therapeutic in the future.

We have also localized the m366.6 epitope by using a combination of computational structural modeling, display-based antigen mutagenesis, and sequence-based analysis of mutants. The epitope appears to overlap with the epitope previously explored as targets for cross-reactive murine mAbs and close to or partially overlaps the dimerization interface between domains II and III. This further indicates that this epitope could be an important component of vaccine immunogens intended to elicit cross-reactive neutralizing antibodies. In progress are our experiments to crystallize the complex of m366.6 with DENV DIII that would allow precise determination of the m366.6 epitope.

The major result of this study is the identification of a germline-like human mAb, m366.6, from a naïve yeast antibody library which binds with high (picomolar) affinity to DIIIs from all serotypes and neutralizes the four DENV serotypes. There are two major implications from this finding: 1) m366.6 is a potential candidate therapeutic which could be further developed in preclinical and clinical settings. 2) the epitope of the germline-like mAb m366.6 could guide the design of effective candidate vaccine immunogens capable of eliciting m366.6 and/or m366.6-like antibodies.

**Materials and methods**

**Cell lines and viruses**

BHK21 cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Biowest). Mosquito cells C6/36 were cultured in RPMI-1640 medium supplemented with 10% FBS. All cells were maintained in a humidified atmosphere of 5% \(\text{CO}_2\) at 37°C incubator, except for C6/36 cells, which were cultivated at 28°C. DENV-1 128 (GenBank FJ176780), DENV-1 GZ01/2017 (isolated from DENV-1 infected patient in Guangzhou), DENV-2 43 (GenBank AF204178), DENV-3 80–2 (GenBank AF317645), and DENV-4 B5 (GenBank AF289029) were propagated in C6/36 cells by using RPMI 1640 medium and the titers were measured by standard plaque forming assay in BHK21 cells.

**Protein expression and purification**

DENV DIII genes from all 4 serotypes were synthesized by Genescript, Inc (Nanjing, China), fused with IgG1 Fc and a C-terminal Avi-tag, and cloned into pSecTag expression vector. The DIII.3 (serotype 3) K310E mutant was generated through overlapping PCR. For the conversion of IgG1 from scFv, the heavy and light chains of scFv were amplified and recloned into the PTT-IgG1 vector. The plasmids were transfected into Expi293 cells (Thermo Fisher) for transient expression, and purified using protein G column (GE Healthcare, Piscataway, NJ) according to the manufacturer’s instructions. The purified protein was biotinylated by mixing...
with biotinylation reagents in PBS for 30 min on ice, according to the manufacturer’s instructions (Pierce).

**Antibody screening from yeast library**

A large yeast-displayed scFv library was used for antibody screening, and the screening protocols were essentially carried out as described previously [55]. Briefly, 10 μg of biotinylated DIII.3-Fc and 10^10 cells of the initial naïve library were mixed and washed by PBSA, and incubated with 100 μl streptavidin conjugated microbeads (Miltenyi Biotec, Auburn, CA) before loading onto the autoMACS system (Miltenyi Biotec) for sorting. After three rounds of sorting, the downsized library was further sorted against biotinylated DIII.3-Fc (1 μg/ml) but also using unbiotinylated K310E mutant (1 μg/ml) as the competitor. The cells were stained by the addition of mouse anti-c-Myc antibody (Roche), Alexa-488 conjugated goat-anti-mouse antibody (Invitrogen), and PE-conjugated streptavidin (Invitrogen) for sorting on a FACSAria II cell sorter (BD Biosciences, San Jose, CA) to isolate the positive binders. The plasmids of the positive clones were prepared by using Zippy Plasmid Miniprep Kit according to the manufacturer’s instructions (Zymo Research).

**Mutant library construction through error-prone and DNA shuffling PCR**

To generate the m360 scFv and m366 scFv mutant libraries, random mutagenesis of the scFv genes were performed through error-prone PCR by using a GeneMorph II kit (Stratagene) following the manufacturer’s instructions with minor modifications. To further diversify the mutation profile, 3 uM of each of the two nucleotide analogues (8-oxo-deoxyguanosine triphosphate and 2′-deoxy-p-nucleoside-5′-triphosphate) was mixed in the PCR reaction mixture. For the second and third cycle library constructions, an extra step of DNA shuffling PCR was inserted into the regular PCR cycles to combine the beneficial mutations obtained from previous maturation process. DNA shuffling PCR step was performed as following: 20 cycles of denature at 94 °C for 15 seconds followed by annealing/extension at 68 °C for 1 second on the Bio-Rad MyCycler.

**Affinity determination by Surface Plasmon Resonance**

Binding affinities of m360 scFv, m366 scFv, m360.6 scFv, and m366.6 scFv to the 4 DENV DIIIs were analyzed by surface plasmon resonance technology using a Biacore X100 instrument (GE healthcare). The antibodies were covalently immobilized onto a sensor chip (CM5) using carbodiimide coupling chemistry. A control reference surface was prepared for nonspecific binding and refractive index changes. For analysis of the kinetics of interactions, varying concentrations of antigens were injected at flow rate of 30 μl/min using running buffer containing 10mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% Surfactant P-20 (pH 7.4). The association and dissociation phase data were fitted simultaneously to a 1:1 Langmuir global model by using the nonlinear data analysis program BIAevaluation 3.2. All the experiments were done at 25 °C.

**DENV PRNT**

Neutralizing activity of mAbs was measured using a standard plaque reduction neutralization with BHK21 cells as previously described [57]. Briefly, 5-fold serial dilutions of mAbs were added to approximately 200 PFU of a variety of dengue virus strains and incubated for 1 h at 37 °C. Then, the mixture was added to BHK21 cell monolayers in a 12-well plate in duplicate and incubated for 1 h at 37 °C. The mixture was removed, and 1 ml of 1.0% (w/v) LMP agarose
(Promega) in DMEM plus 4% (v/v) FBS was layered onto the infected cells. After further incubation at 37 °C for 4 days, the wells were stained with 1% (w/v) crystal violet dissolved in 4% (v/v) formaldehyde to visualize the plaques. PRNT_{50} values were determined using non-linear regression analysis. PRNT_{50} data were calculated by doing a non-linear regression analysis using Sigmaplot (Version 9.01, Systat Software, Inc., CA) as previously described [57].

**DENV RVP neutralization assay**

DENV RVPs from all four serotypes were pre-incubated with an equal volume of serially diluted antibodies (25 μg/ml to 0.0012 μg/ml pre-dilution or 12.5 μg/ml to 0.0006 μg/ml pre-dilution, as measured based on the dilution of antibody prior to combining with RVPs) in DMEM infection media for 1 h at room temperature and transferred to wells of a 96-well plate. An equal volume of DENV RVPs were added to each well followed by slow agitation for 1 h at room temperature. BHK DC-SIGN cells were added to each well at a density of 30,000 cells per well followed by incubation at 37°C in 5% CO₂ for 48 h. Cells were subsequently fixed in lysed and analyzed for luminescent reporter expression using the Wallac Victor. The percent infection for each concentration of mAb or serum was calculated, and the raw data was expressed as percent infection versus log₁₀ of the mAb concentration or the reciprocal serum dilution. The data were fitted to a sigmoidal dose-response curve using Prism (GraphPad Software, La Jolla, CA) to determine the titer of antibody that achieved a 50% reduction in infection. Maximum infection was determined in the absence of antibodies.

**DENV ADE assay**

The in vitro ADE assay was performed using K562 cells [57]. Briefly, serial 10-fold dilutions of antibodies under concentrations ranging from 100 to 0.01 μg/ml were mixed with DENV-1 or DENV-2, and incubated for 1 h at 37 °C. Mixtures were then added to 2×10⁵ K562 cells at multiplicity of infection of 0.1~0.25 for 2 h in 24-well plates. The cells were subsequently washed 3 times with serum free RPMI-1640 medium. After collecting cells by centrifugation, the cell pellets were re-suspended with RPMI-1640 medium containing 2% FBS and added to 24-well plates, then incubated for 4 days at 37 °C with 5% CO₂. The titer of viruses in the supernatant was then measured using a plaque assay. The ADE effect was calculated as different viral yields in the supernatant after infection in the presence of the added antibodies.

**Epitope mapping of m366.6 through DIII mutant library sorting**

The epitope mapping of m366.6 was performed using previously described protocols [55]. Briefly, random mutagenesis of the DENV DIII.2 gene was performed using a GeneMorph II kit (Stratagene). As described above, the yeast-displayed mutant library was mixed with biotinylated m366.6 scFv-Fc, washed, and stained by mouse anti-c-Myc antibody (Roche), Alexa-488 conjugated goat-anti-mouse antibody (Invitrogen), and PE-conjugated streptavidin (Invitrogen). After two rounds of sorting on a FACSaria II cell sorter (BD Biosciences, San Jose, CA), the sorted cells were amplified and their plasmids were prepared and sequenced.

**Computational docking of the DIII-m366.6 antibody complex**

Homology modeling of variable regions of heavy (V_{H}) and light (V_{L}) chains for m366.6 scFv antibody was carried out using the SWISS-MODEL workspace [68] by selecting the closest template structures (PDB codes: 3QOS for heavy chain and 2DD8 for light chain), whose sequence similarities were 92% and 87% respectively. The V_{H}-V_{L} orientation of m366.6 scFv structure was assigned similar with one of the templates (PDB code: 2DD8) that showed
minimum steric clash for creating the final m336.6 scFv model. The crystal structure of DENV DIII serotype 2 (PDB code: 2R29) was used for docking with the modeled scFv antibody m366.6. Docking of scFv m336.6 to the dengue Env-III was performed by ZDOCK server (http://zdock.bu.edu) that uses a fast Fourier transform (FFT)-based rigid-body protein docking algorithm with scoring functions combining pairwise shape complementarity, desolvation and electrostatic energies. Based on the escape mutants that led to the loss of epitopes and available crystal structure of DENV DIII, we selected a list of residues as biological constrains, 307, 309, 310, 311, 327, 361 and 383, on the surface of Env-DIII as potential contacting residues for docking constraints. Similarly, one or two residues from each of CDR-H1, H3 and L3 loops were chosen at the docking interface. CDR-H1 and H3 loops had dominant hydrophobic residues whereas CDR-L1 had a germline mutation, and they all had high antigen-contacting propensities [69]. Results from the top 2000 ZDOCK predictions were filtered using the user-defined residues and a 6 angstrom distance cutoff. Three predicted complexes were only kept as all residues selected come together at the interface and were further examined by PDBePISA (Protein Interfaces, Surfaces and Assemblies). PyMOL was used for the analysis of docked model and graphical illustration [70].

In vivo therapeutic experiments

The suckling mice were purchased from B&K Universal Group Limited (Shanghai, China) and housed under specific pathogen-free conditions at the animal facilities of the Shanghai Public Health Clinical Center, Fudan University (Shanghai, China). Before infection, the mice were transferred to the Animal Biosafety Level 2 (BSL-2) Laboratory (Shanghai, China). One day mice were used for all experiments. All mice were intracerebrally injected with 200 PFU of DENV1-4. At 4 h post infection, mice were passively transferred a single dose of 100 μg antibody m366.6 IgG, m366.6 IgG LALA mutant or G12 IgG as the negative control via intracerebrally injection. Survival rates and disease sings were monitored daily. The AG129 mice (type I and type II interferon receptor-deficient) were purchased from B&K Universal Group Limited (Shanghai, China) and housed under specific pathogen-free conditions at the animal facilities of the Shanghai Public Health Clinical Center, Fudan University (Shanghai, China). Before infection, the mice were transferred to the BSL-2 Laboratory (Shanghai, China). Groups of mixed-sex 4- to 6-week-old mice were used for all experiments. All mice were intraperitoneally injected with 2x10⁶ PFU of DENV-2 in a volume of 200 μL. At 16 h post infection, mice were passively transferred a single dose of 500 μg antibody m366.6 IgG-LALA, or G12 antibody as the control via i.p. injection. Survival rates, weight loss, and disease sings were monitored daily.

Ethics statement

Specific-pathogen-free AG129 mice (4–6 weeks old) and suckling mice were used for all experiments. All experimental protocols were reviewed and approved by the institutional committee of Fudan University (Permit Number: 2018-A056-02) in accordance with the Guideline for Ethical Review of Animal Welfare (GB/T 35892–2018) of the Chinese National Health and Medical Research Council (NHMRC).

Supporting information

S1 Fig. Binding of m360 to DENV DIIIs from the four serotypes measured by Biacore. The m360 was immobilized onto a CM5 chip, and the analytes consisted of serial dilution of DIII
from DENV-1 (A), DENV-2 (B), DENV-3 (C), or DENV-4 (D). Binding kinetics was fitted using a 1:1 Langumir binding model by BIAevaluation 3.2 software.

S2 Fig. Binding of m366 to DENV DIIIs from the four serotypes measured by Biacore. The m366 was immobilized onto a CM5 chip, and the analytes consisted of serial dilution of DIII from DENV-1 (A), DENV-2 (B), DENV-3 (C), or DENV-4 (D). Binding kinetics was fitted using a 1:1 Langumir binding model by BIAevaluation 3.2 software.

S3 Fig. Binding of m360.6 to DENV DIIIs from the four serotypes measured by Biacore. The m360.6 was immobilized onto a CM5 chip, and the analytes consisted of serial dilution of DIII from DENV-1 (A), DENV-2 (B), DENV-3 (C), or DENV-4 (D). Binding kinetics was fitted using a 1:1 Langumir binding model by BIAevaluation 3.2 software.

S4 Fig. Binding of m366.6 to DENV DIII, ZIKV DIII, gp140 and PDL1 proteins measured by ELISA.

S5 Fig. Broad neutralization of the four DENV serotypes by m360.6 and m366.6. (A-D) Infectivity of DENV RVPs for all four serotypes. RVPs for DENV-1 (WestPac), DENV-2 (S16803), DENV-3 (CH53489) or DENV-4 (TVP360) were serially diluted in DMEM. BHK DC-SIGN cells were added and cells were cultured for 72 h. The cells were then lysed and examined for reporter expression. The independent neutralization experiments were performed in duplicate.

S6 Fig. The complete sequence of DENV-1 GZ01/2017, a dengue virus isolated from a DENV-1 infected patient in Guangzhou, China.

S7 Fig. ADE activity of antibodies against DENV-2. DENV-2 was incubate with 10-fold serial dilutions of mAbs before added to K562 cells. Virus in the supernatant of infected K562 cells was quantified in a plaque assay. The data were shown as means ± SD. The dotted line indicates the limit of detection.

S8 Fig. In vivo therapeutic efficacy of m366.6 against DENV-2 infection. For therapeutic efficacy study, AG129 mice were treated intraperitoneally with and m366.6 IgG-LALA 16 h after viral challenge with 2x10⁶ PFU of DENV-2, and were monitored daily for 12 days for the accumulated mortality (n = 6 per group). Unrelated antibody G12 was used for the control group.

Acknowledgments

We thank Professor Dane Wittrup from MIT for providing the yeast display vector and yeast strain.

Author Contributions

Conceptualization: Dimiter S. Dimitrov, Tianlei Ying.
Investigation: Dan Hu, Zhongyu Zhu, Shun Li, Yongqiang Deng, Yanling Wu, Nana Zhang, Vinita Puri, Chunyu Wang, Cheng Lei, Xiaolong Tian, Yulu Wang, Qi Zhao, Wei Li, Ponraj Prabakaran, Yang Feng, Jane Cardosa, Chengfeng Qin.

Supervision: Xiaohui Zhou, Dimiter S. Dimitrov, Tianlei Ying.

Writing – original draft: Dan Hu, Zhongyu Zhu.

Writing – review & editing: Tianlei Ying.

References

1. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, et al. (2006) The WHO dengue classification and case definitions: time for a reassessment. Lancet 368: 170–173. https://doi.org/10.1016/S0140-6736(06)69006-5 PMID: 16829301

2. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71–92. https://doi.org/10.1146/annurev.micro.62.081307.163005 PMID: 18429680

3. Aguiar M, Stollenwerk N, Halstead SB (2016) The risks behind Dengvaxia recommendation. The Lancet Infectious Diseases 16: 882–883. https://doi.org/10.1016/S1473-3099(16)30168-2 PMID: 27477967

4. Aguiar M, Stollenwerk N (2018) Dengvaxia: age as surrogate for serostatus. The Lancet Infectious Diseases 18: 245. https://doi.org/10.1016/S1473-3099(17)30752-1 PMID: 29276049

5. Fatima K, Syed NI (2018) Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health 8: 010312. https://doi.org/10.7189/jogh.08-020312 PMID: 30410732

6. Martinez-Vega RA, Carrasquillo G, Luna E, Ramos-Castaneda J (2017) ADE and dengue vaccination. Vaccine 35: 3910–3912. https://doi.org/10.1016/j.vaccine.2017.06.004 PMID: 28623027

7. Halstead SB (2007) Dengue. Lancet 370: 1644–1652. https://doi.org/10.1016/S0140-6736(07)61687-0 PMID: 17993365

8. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745–748. https://doi.org/10.1126/science.1185181 PMID: 20448183

9. Marasco WA, Sui J (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nature biotechnology 25: 1421–1434. https://doi.org/10.1038/nbt1363 PMID: 18066039

10. Modi Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 1223–1231. https://doi.org/10.1128/JVI.79.2.1223-1231.2005 PMID: 15613349

11. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328. https://doi.org/10.1006/viro.1998.9200 PMID: 9657950

12. Bedouelle H, Belkadi L, England P, Guijarro JI, Lisova O, et al. (2006) Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J 273: 34–46. https://doi.org/10.1111/j.1742-4658.2005.05045.x PMID: 16367746

13. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82: 1885–1892. https://doi.org/10.1099/0022-1317-82-8-1885 PMID: 11457994

14. Huerta V, Chinea G, Fleitas N, Sarria M, Sanchez J, et al. (2008) Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res 137: 225–234. https://doi.org/10.1016/j.virusres.2008.07.022 PMID: 18723056

15. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 85: 7769–7773. https://doi.org/10.1128/JVI.75.16.7769-7773.2001 PMID: 11462053

16. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229–238. https://doi.org/10.1016/j.chom.2008.08.004 PMID: 18779049

17. Fibriansah G, Lok SM (2016) The development of therapeutic antibodies against dengue virus. Antiviral Res 128: 7–19. https://doi.org/10.1016/j.antiviral.2016.01.002 PMID: 26794397

18. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631–6643. https://doi.org/10.1128/JVI.00316-08 PMID: 18448542
19. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, et al. (2016) Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 17: 1102–1108. https://doi.org/10.1038/ni.3515 PMID: 27339099

20. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, et al. (2016) Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A 113: 7852–7857. https://doi.org/10.1073/pnas.1607931113 PMID: 27354515

21. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188. https://doi.org/10.1371/journal.pntd.0001188 PMID: 21713020

22. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790. https://doi.org/10.1371/journal.ppat.1000790 PMID: 20168989

23. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271–283. https://doi.org/10.1016/j.chom.2010.08.007 PMID: 20833378

24. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84: 9227–9239. https://doi.org/10.1128/JVI.01087-10 PMID: 20592088

25. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823. https://doi.org/10.1371/journal.ppat.1000823 PMID: 20369024

26. Rajamanonmani R, Nkenfo C, Clancy P, Yau YH, Shochat SG, et al. (2009) On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90: 799–809. https://doi.org/10.1099/vir.0.021220-0 PMID: 19264660

27. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 12816–12826. https://doi.org/10.1128/JVI.00432-07 PMID: 17881453

28. Gromowsk i GD, Roehrig JT, Diamond MS, Lee JC, Pitcher TJ, et al. (2010) Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407: 237–246. https://doi.org/10.1016/j.virol.2010.06.044 PMID: 20832836

29. Matsui K, Gromowsk i GD, Li L, Barrett AD (2010) Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. J Gen Virol 91: 2249–2253. https://doi.org/10.1099/vir.0.021220-0 PMID: 20444995

30. Liu Y, Zhang F, Liu J, Xiao X, Zhang S, et al. (2014) Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention. PLoS Pathog 10: e1003931. https://doi.org/10.1371/journal.ppat.1003931 PMID: 24550728

31. Matsui K, Gromowsk i GD, Li L, Schuh AJ, Lee JC, et al. (2009) Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384: 16–20. https://doi.org/10.1016/j.virol.2008.11.013 PMID: 19101005

32. Gromowsk i GD, Barrett ND, Barrett AD (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828–8837. https://doi.org/10.1128/JVI.00606-08 PMID: 18562544

33. Gromowsk i GD, Barrett AD (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349–360. https://doi.org/10.1016/j.virol.2007.05.042 PMID: 17719070

34. Hiramatsu K, Tadano M, Men R, Lai CJ (1996) Mutational analysis of a neutralization epitope on the dengue type 2 virus (DENV2) envelope protein: monoclonal antibody resistant DENV2/DENV4 chimeras exhibit reduced mouse neurovirulence. Virology 224: 437–445. https://doi.org/10.1006/virol.1996.0550 PMID: 8874504

35. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312–317. https://doi.org/10.1038/nsmb.1382 PMID: 18264114

36. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9: 137–147. https://doi.org/10.1586/erv.09.139 PMID: 20190925

37. Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, et al. (2011) The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 29: 4256–4263. https://doi.org/10.1016/j.vaccine.2011.03.040 PMID: 21447316
38. Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, et al. (2009) Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 16: 1825–1831. https://doi.org/10.1128/CVI.00191-09 PMID: 19726617

39. Liu Y, Liu J, Cheng G (2016) Vaccines and immunization strategies for dengue prevention. Emerg Microbes Infect 5: e77. https://doi.org/10.1038/emi.2016.74 PMID: 27436365

40. Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, et al. (2008) Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 138: 135–138. https://doi.org/10.1016/j.viruses.2008.08.008 PMID: 18796319

41. Simmons M, Nelson WM, Wu SJ, Hayes CG (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655–662. https://doi.org/10.4269/ajtmh.1998.58.655 PMID: 9598457

42. Simmons M, Murphy GS, Hayes CG (2001) Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65: 159–161. https://doi.org/10.4269/ajtmh.2001.65.159 PMID: 11508393

43. Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr. (1995) Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13: 1251–1258. PMID: 8578812

44. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, et al. (2011) An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 85: 410–421. https://doi.org/10.1128/JVI.01826-10 PMID: 20980526

45. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103–113. https://doi.org/10.1016/j.virol.2009.06.037 PMID: 19631955

46. Yu F, Song H, Wu Y, Chang SY, Wang L, et al. (2017) A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe 22: 471–483 e475. https://doi.org/10.1016/j.chom.2017.08.011 PMID: 28966056

47. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, et al. (2014) Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88: 7796–7805. https://doi.org/10.1128/JVI.00912-14 PMID: 24789777

48. Ying T, Prabakaran P, Du L, Shi W, Feng Y, et al. (2015) Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun 6: 8223. https://doi.org/10.1038/ncomms9223 PMID: 26370782

49. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, et al. (2017) Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell 31: 501–515 e508. https://doi.org/10.1016/j.ccell.2017.03.005 PMID: 28399408

50. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, et al. (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24: 20–28. https://doi.org/10.1038/nm.4441 PMID: 29155426

51. Hong B, Wu Y, Li W, Wang X, Wen Y, et al. (2018) In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. Front Immunol 9: 128. https://doi.org/10.3389/fimmu.2018.00128 PMID: 29459861

52. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T (2017) Human monoclonal antibodies as candidate therapeutics against emerging viruses. Front Med 11: 462–470. https://doi.org/10.1007/s11684-017-0596-6 PMID: 29159596

53. Puri V, Streaker E, Prabakaran P, Zhu Z, Dimitrov DS (2013) Highly efficient selection of epitope specific antibody through competitive yeast display library sorting. MAbs 5: 533–539. https://doi.org/10.4161/mabs.25211 PMID: 23765162

54. Wang W, Sun L, Li T, Ma Y, Li J, et al. (2016) A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect. MAbs 8: 486–477. https://doi.org/10.1080/19420862.2015.1134409 PMID: 26713590

55. Shi X, Deng Y, Wang H, Ji G, Tan W, et al. (2016) A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. MAbs 8: 574–584. https://doi.org/10.1080/19420862.2016.1148850 PMID: 26905804
58. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, et al. (2011) A broadly flavivirus cross-neutralizing mono-clonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 6: e16059. https://doi.org/10.1371/journal.pone.0016059 PMID: 21264311

59. Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2: 347–356. https://doi.org/10.4161/mabs.2.3.11779 PMID: 20400863

60. Huang J, Kang BH, Pancera M, Lee JH, Tong T, et al. (2014) Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515: 138–142. https://doi.org/10.1038/nature13601 PMID: 25186731

61. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412. https://doi.org/10.1038/nature11544 PMID: 23151583

62. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2014) Broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817. https://doi.org/10.1126/science.1192819 PMID: 20616231

63. Gao R, Cao B, Hu Y, Feng Z, Wang D, et al. (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888–1897. https://doi.org/10.1056/NEJMoa1304459 PMID: 23577628

64. Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, et al. (2014) Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6: 242ra282.

65. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, et al. (2007) Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 104: 12123–12128. https://doi.org/10.1073/pnas.0701000104 PMID: 17620608

66. Wang Q, Bi W, Zhu X, Li H, Qi Q, et al. (2015) Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. J Virol 89: 6960–6964. https://doi.org/10.1128/JVI.00791-15 PMID: 25903343

67. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, et al. (2015) A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16: 170–177. https://doi.org/10.1038/ni.3058 PMID: 25501631

68. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, et al. (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42: W252–258. https://doi.org/10.1093/nar/gku340 PMID: 24782522

69. MacCallum RM, Martin AC, Thornton JM (1996) Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262: 732–745. https://doi.org/10.1006/jmbi.1996.0548 PMID: 8876650

70. Mooers BH (2016) Simplifying and enhancing the use of PyMOL with horizontal scripts. Protein Sci 25: 1873–1882. https://doi.org/10.1002/pro.2996 PMID: 27488983